Published in Pharma Law Weekly, July 14th, 2009
"We designed novel pyrosequencirig assays for the detection of the common ''hotspot'' mutations in these genes, which demonstrated analytical sensitivities of <= 10% in titrations of mutant cell lines. The KRAS pyrosequencing assay has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly